Pharma Focus America

Lilly Obtains Exclusive Global License for QRL-204 from QurAlis: Innovative Therapy Targeting ALS and FTD

Tuesday, June 04, 2024

QurAlis Corporation has recently announced an exclusive licensing agreement with Eli Lilly and Company, granting Lilly global rights to develop and commercialize QRL-204, an antisense oligonucleotide (ASO) designed to restore UNC13A function in neurodegenerative diseases like ALS and FTD.

As part of the deal, QurAlis received an upfront payment of $45 million from Lilly, along with an additional equity investment. Additionally, QurAlis stands to receive future milestone payments totaling up to $577 million, as well as royalties based on net sales.

The agreement also includes a research and development collaboration to identify and develop additional candidates targeting UNC13A, utilizing QurAlis' proprietary FlexASO™ Splice Modulator Platform. This platform aims to generate splice-switching ASOs with improved potency and therapeutic efficacy.

Andrew Adams, senior vice president of neurodegeneration research at Lilly, expressed excitement about the collaboration and the potential of genetic precision medicines like QRL-204 to target specific disease pathways.

QurAlis, echoed this enthusiasm, highlighting the accelerated development path for QRL-204 enabled by the partnership.

UNC13A plays a crucial role in neurotransmitter release regulation, and its dysfunction is implicated in diseases like ALS and FTD. QurAlis' preclinical data, presented at the AD/PD™ 2024 Conference, demonstrated promising outcomes in restoring synaptic function in ALS and FTD models through the modulation of UNC13A splicing by their ASOs.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024